SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-074559
Filing Date
2024-08-30
Accepted
2024-08-30 16:30:38
Documents
74
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0212098-6k_enlivex.htm   iXBRL 6-K 16906
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR ENLIVEX AS OF JUNE 30, ea021209801ex99-1_enlivex.htm   iXBRL EX-99.1 541533
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF AND FOR THE THREE AND SIX MON ea021209801ex99-2_enlivex.htm EX-99.2 94901
  Complete submission text file 0001213900-24-074559.txt   4497241

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enth-20240630.xsd EX-101.SCH 54491
5 XBRL CALCULATION FILE enth-20240630_cal.xml EX-101.CAL 40066
6 XBRL DEFINITION FILE enth-20240630_def.xml EX-101.DEF 214867
7 XBRL LABEL FILE enth-20240630_lab.xml EX-101.LAB 425837
8 XBRL PRESENTATION FILE enth-20240630_pre.xml EX-101.PRE 229724
77 EXTRACTED XBRL INSTANCE DOCUMENT ea0212098-6k_enlivex_htm.xml XML 624317
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 241270566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)